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M ore than 50 years have passed since theFramingham Heart Study investigatorspublished their ﬁrst major report on
“risk factors” for coronary heart disease (1). Kannel
et al. (1) discovered 3 risk factors, namely elevated
blood pressure, elevated cholesterol levels, and elec-
trocardiographic left ventricular hypertrophy. These
discoveries stimulated decades of research efforts,
which revolutionized our approach to hypertension
and hypercholesterolemia. There is little question
that much of the 50-year decline in cardiovascular
disease death rates can be partially attributed
to the seminal contributions of the Framingham
epidemiologists.
Within a few months of the Framingham publica-
tion, Dr. George Saiger of Columbia University
published a commentary on the “10 uses of epide-
miology” (2). In the early 1960s, scientists were
coming to recognize that epidemiology as a ﬁeld was
expanding beyond infectious disease. Saiger’s 10 uses
included measuring risk, aiding in the search for
causes of disease, and identifying pre-symptomatic
disease. More recently, Colditz and Winn (3) broke
down the purposes of epidemiology into 3 “Ds,” dis-
covery, development, and delivery. They included
in development “contribution to determination of
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risk models.”In this issue of the Journal, Jorgensen et al. (4)
report an epidemiological investigation on the asso-
ciation of electrocardiographic changes and cardio-
vascular risk in asymptomatic persons older than
65 years. The investigators obtained baseline elec-
trocardiograms in 6,991 Copenhagen Heart Study
participants and followed them for nearly 12 years,
during which time 2,236 fatal cardiovascular di-
sease events occurred. Baseline electrocardiographic
abnormalities were common. These included left
ventricular hypertrophy, intermediate or major
ST-segment depressions, intermediate or major
T-wave changes, ventricular conduction defects, and
intermediate or major Q waves. By the continuous net
reclassiﬁcation index, the strongest electrocardio-
graphic predictors of fatal cardiovascular disease
events were T-wave changes, ST-segment de-
pressions, resting heart rate, and left ventricular
hypertrophy.
The report by Jorgenson et al. (4) reﬂects solid
epidemiology research. The investigators identiﬁed
and carefully characterized a population-based in-
ception cohort. During years of systematic follow-up,
they collected data on a large number of hard clinical
outcome events. They considered several types of
electrocardiographic measures, not just those that
might reﬂect myocardial ischemia. They used cutting-
edge analytical methods, including describing each
electrocardiographic variable’s impact on measures
of model discrimination and reclassiﬁcation (5).
Also, to their credit, the investigators did not
overinterpret their results. They correctly noted that
the U.S. Preventive Services Task Force recommends
against screening electrocardiography, as there is no
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908high-quality clinical trial evidence of improved clin-
ical outcomes (6). The current investigation, while
showing that electrocardiography can improve risk
estimation, in no way changes the appropriateness of
the task force’s recommendation. The investigators
also acknowledged that they did not have access to
digital measures; recent investigations have shown
that digital electrocardiography reveals the prog-
nostic value of short-term heart rate variability, a
measure of autonomic nervous system balance (7).
By the criteria described by Saiger (2) and more
recently articulated by Colditz and Winn (3), the work
of Jorgensen et al. (4) nicely illustrates the value of
epidemiological investigations. The current work
would justify additional basic science and clinical
investigations into the links between left ventricular
hypertrophy, other electrocardiographic abnormali-
ties, and cardiovascular risk. The work demon-
strates the potential value of electrocardiography for
improving risk prediction and for deﬁning pre-
symptomatic disease.
At the same time, though, this report on what we
might call “electrocardiographic epidemiology” il-
lustrates the challenges facing modern epidemi-
ology. The Joint Policy Committee of the Societies of
Epidemiology recently described a number of chal-
lenges and opportunities (8). They called on epide-
miologists to better communicate the nature of their
work; to better incorporate modern methodological
approaches; to ensure widespread data access; to
take into account evolving ethical principles as
research and clinical medicine become increasingly
intertwined; to better incorporate molecular, ge-
netic, pharmaco-epidemiological, and comparative-
effectiveness methods; and to account for dynamic
factors shaping human health. In separate calls for
transformative changes in epidemiology (9) and clin-
ical research (10), I have noted the need for refocused
scientiﬁc questions that take into account the tapestry
of complex exposure and outcome variables and the
need for scientists to appreciate the potential beneﬁts
of embedding clinical trials into epidemiological
studies.
Keeping these challenges in mind, what might the
future of electrocardiographic epidemiology be? How
might the scientiﬁc community leverage modern-day
technologies and scientiﬁc constructs to betterunderstand why measures such as electrocardio-
graphic left ventricular hypertrophy, ST-segment and
T-wave changes, and short-term heart variability
predict risk? We might imagine that epidemiologists
and other scientists would band together to blend
many “-omes”– the genome, transcriptome, prote-
ome, metabolome, and exposome (including eco-
nomic, social, and environmental contributors to ill
health) – all together with a new -ome, the “electro-
cardio-ome.” Using digital mobile technology and
microﬂuidics (11), scientists could describe the
electrocardio-ome as an -ome with thousands to mil-
lions of data points in time and space. They could
combine the electrocardio-ome and other “classic”
-omes in huge cohorts, and analyze its link to
disease with modern-day methods, including systems
modeling, machine learning, and Mendelian random-
ization (8). Armed with these epidemiological ﬁnd-
ings, basic scientists might have a better chance
of identifying novel target pathways that would
lend themselves to preventive or therapeutic in-
terventions. Eventually, the process would circle back
to clinical and population spheres where clinical sci-
entists would conduct large-scale, low-cost trials to
delineate which interventions should be actionable at
clinical or public policy levels.
Despite >50 years of progress, we have not yet
ﬁgured out how to translate the Framingham in-
vestigators’ discovery of the excess risk associated
with electrocardiographic left ventricular hypertro-
phy into effective targeted interventions for preven-
tion and treatment (12). The current report by
Jorgensen et al. (4) reinforces the potential impor-
tance of electrocardiographic measures in assessing
risk. Just as the original Framingham report stimu-
lated a highly productive era in hypertension and
hypercholesterolemia research, the current Copen-
hagen Heart Study report, along with others like it,
might stimulate a new era of “electrocardio-omic”
research, which might bring us closer to a world free
of cardiovascular disease.
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